AbbVie Raises Q4 EPS Guidance to $3.32–3.36; Commerzbank Sells 30.5% Stake
Commerzbank cut its AbbVie stake by 30.5% to 90,102 shares (worth $20.9 million) in Q3, while First Citizens Bank trimmed its position by 6.5% to 34,834 shares. AbbVie raised its Q4 2025 EPS guidance to $3.32–3.36 and boosted its quarterly dividend to $1.73 per share (3.2% yield).
1. Commerzbank Reduces Stake Significantly
In the most recent SEC 13F filing, Commerzbank Aktiengesellschaft FI disclosed a 30.5% reduction in its position in AbbVie, selling 39,586 shares during the third quarter. Following this sale, the institution now holds 90,102 shares of the company, representing a shift in its allocation of approximately $20.9 million at the end of the period.
2. Dividend Hike Reinforces Income Profile
AbbVie announced a quarterly dividend increase from $1.64 to $1.73 per share, marking a 5.5% rise. This adjustment raises the annualized dividend to $6.92 per share, translating into a current yield of 3.2%. The move underscores the company’s commitment to returning capital to shareholders, though it brings the payout ratio to 524.24%, reflecting the balance between cash distribution and earnings generation.
3. Third-Quarter Results Exceed Expectations
For its latest quarter, AbbVie reported earnings per share of $1.86, surpassing consensus estimates by $0.09. Revenue reached $15.78 billion, beating forecasts by $200 million and reflecting a 9.1% year-over-year increase. The company reiterated its full-year guidance of $3.320 to $3.360 in fourth-quarter EPS and analysts have since penciled in 12.31 EPS for the current fiscal year.
4. Analyst Consensus Remains Constructive
MarketBeat data shows a consensus rating of "Moderate Buy" for AbbVie, based on coverage from 23 analysts. Two have assigned a Strong Buy, thirteen maintain Buy ratings and eight recommend Hold. The average target price stands at $248.11, indicating analyst expectations for further upside potential against current valuation metrics.